Colorectal cancer (CRC) is the third most prevalent malignant tumor globally and is associated with high morbidity and mortality rates. The advancement of novel nanocarrier-based drug delivery systems has revolutionized therapeutic strategies for colonic drug delivery and cancer treatment. This review provides updated insights into various nanocarrier technologies, including quantum dots (QDs), polymeric nanoparticles (PNPs), magnetic and metallic nanoparticles, solid lipid nanoparticles (SLNs), and self-microemulsifying and self-nanoemulsifying drug delivery systems (SMEDDS/SNEDDS). These nanocarriers offer enhanced drug stability, controlled release, and targeted delivery, particularly for CRC treatment, resulting in up to 70 % improved therapeutic efficacy and a significant reduction in systemic toxicity as reported in preclinical studies. The review comprehensively discusses the structural composition, mechanisms of action, therapeutic potential, and imaging capabilities of these systems, with a focus on their applications in theranostics and targeted CRC therapy. For instance, polymeric nanoparticles have demonstrated a 50 % increase in bioavailability compared to conventional formulations, while QDs have enabled real-time imaging with high precision for tumor localization. Additionally, the toxicity profiles and challenges associated with these nanocarriers are critically evaluated. Despite significant progress in preclinical and clinical studies, the review highlights the need for optimizing biocompatibility, scalability, and regulatory standards to facilitate the clinical translation of these promising technologies. Emerging formulations such as graphene quantum dots and PEGylated nanoparticles have shown potential for achieving dual therapeutic and diagnostic applications with fewer adverse effects. Overall, nanocarrier-based systems hold great potential for personalized and more effective treatments in colon-targeted therapies.